GlaxoSmithKline Pharmaceutical, a leading MNC in India, has suffered a setback during the 15 months period ended March 2015 and its consolidated net profit on an annualised basis declined by 20.9 per cent to Rs.381.12 crore from Rs.481.67 crore in the year ended December 2013. Its annualised consolidated net sales improved marginally by 3.1 per cent to Rs.2,618 crore from Rs.2,538 crore. EPS for 15 months period worked out to Rs.56.2 as against Rs.56.9 in the last year.

The board of directors has recommended handsome equity dividend of Rs.62.50 per share for the year 2014-15 as compared to Rs.50 per share in the previous year.

As against the equity capital of Rs.84.70 crore its reserves & surplus amounted to Rs.1,744 crore as against Rs.1,905 crore in the previous year, de-growth of 8.4 per cent.

Its standalone net sales for the quarter ended March 2015 improved by 2.3 per cent to Rs.613.47 crore from Rs.599.85 crore in the corresponding period of last year. Its standalone net profit increased 6.5 per cent to Rs.102.85 crore from Rs.96.54 crore. The quarterly performance was impacted by supply constraints.

Its standalone net sales for the 15 months period ended amounted to Rs.3,253 crore as compared to Rs.2,520 crore in the previous year of 12 months period. Its standalone net profit, however declined to Rs.471.65 crore from Rs.501.88 crore.

Meanwhile, Simon Harford, non-executive director has retired and the company has appointed Regis Simard as the non-executive director from May 18, 2015. eau, Mumbai